Standout Papers
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (2017)
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial (2017)
Immediate Impact
2 from Science/Nature 54 standout
Citing Papers
Principles and therapeutic applications of adaptive immunity
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
Works of Silke Hoersch being referenced
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
2017 Standout
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Silke Hoersch | 1095 | 447 | 202 | 455 | 16 | 1.5k | |
| Grazyna Liebérman | 1057 | 393 | 231 | 264 | 9 | 1.7k | |
| L. Tagliabue | 479 | 252 | 211 | 146 | 22 | 1.3k | |
| Mary Kathryn Pierri | 866 | 280 | 88 | 344 | 15 | 1.3k | |
| Beverly C. Handy | 983 | 426 | 661 | 301 | 47 | 1.9k | |
| Thomas J. Saphner | 1273 | 389 | 514 | 165 | 30 | 1.8k | |
| Jutta Steinseifer | 967 | 476 | 475 | 203 | 15 | 1.4k | |
| Deborah Keefe | 1299 | 260 | 218 | 512 | 9 | 1.7k | |
| Thomas E. Seay | 1708 | 492 | 547 | 226 | 20 | 2.2k | |
| Nils‐Olof Bengtsson | 1088 | 374 | 747 | 299 | 34 | 2.0k | |
| G. Ross | 1324 | 284 | 552 | 528 | 48 | 1.8k |
All Works
Loading papers...